NON SMALL CELL LUNG CANCER

This study tested a combination of the immunotherapy drug durvalumab and precise, high-dose radiation for people with advanced non-small cell lung cancer. The goal was to see if this approach could improve quality of life and control tumors. However, the trial was terminated earl…

This early-phase trial tested the safety of giving a type of precise radiation (SABR) either before or after the immunotherapy drug pembrolizumab in 13 people with advanced non-small cell lung cancer. The study aimed to see how well patients tolerated the combination and whether …

This early-stage trial tested a new drug called PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung or skin cancer. The goal was to check safety and see if the drug shrinks tumors. However, the study was terminated, so results ar…

This phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was…

This early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…

This study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…

This phase 2 trial tested a combination of two drugs—HBI-8000 (tucidinostat) and pembrolizumab (Keytruda)—in adults with advanced or metastatic non-small cell lung cancer whose tumors have a specific marker (PD-L1 ≥1%). Only 5 people took part, and the study was stopped early. Th…

This early-stage trial tested an experimental gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy drug pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer that had been treated before. The study aimed to find a safe dose …

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This study tested whether giving patients their own immune cells (called lymphocytes) after chemotherapy and radiation could help their immune system recover faster. It included 19 adults with lung or esophageal cancer. The treatment was designed to reduce a common side effect of…

This early-phase study tested a new cell therapy called ITIL-306 in adults with advanced ovarian, lung, or kidney cancers that had stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The s…

This early-phase study aimed to see if adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer before surgery. Only one person took part before the trial was ended. The main goal was to measure immune ce…

This early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped e…

This early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a powerful chemotherapy directly to cancer cells…

This study tested the drug capmatinib, given before and after surgery, in people with a certain type of non-small cell lung cancer (stages IB to IIIB) that has a MET gene change. Only 4 people took part before the trial was stopped early, so there is not enough information to kno…

This early-stage trial tested a new drug called DCC-3116 (inlexisertib) in 91 people with advanced or metastatic solid tumors that have RAS/MAPK pathway mutations. The drug was given alone or combined with other targeted therapies. The study aimed to find safe doses and check for…

This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…

This study tested whether adding canakinumab to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer. About 673 patients took part, but the trial was stopped early. The goal was to control the disease, not …

This early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, colon, kidney, and ovarian cancers. The goal was to check safety, find the right dose, and see if the drug shrinks tumors. Only 10 people…

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This study tested a new treatment for advanced non-small cell lung cancer using a patient's own immune cells (TILs) combined with an immunotherapy drug. The goal was to see if the combination was safe and tolerable. Only 2 people enrolled before the study was stopped early, so re…

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) in people with a type of lung cancer that had spread to the brain but wasn't causing symptoms. The goal was to see if the treatment could control the brain tumors and delay the need for radi…

This study tested a drug called tovorafenib in people aged 12 and older whose cancer had come back or spread. The drug targets tumors with specific genetic changes in the MAPK pathway. The trial was stopped early, but researchers looked at how many patients' tumors shrank and tra…

This study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before th…

This early-stage study tested a new drug (BMS-986258) alone or with another immunotherapy (nivolumab) in people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and side effects. The study was terminated early, so results are limit…

This study tested an experimental drug called telisotuzumab vedotin for people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a MET gene change. The goal was to see if the drug could shrink tumors. The trial was stopped early and e…

This pilot study tested giving immunotherapy (durvalumab, with or without tremelimumab) along with standard radiation before surgery for stage III non-small cell lung cancer. Only 9 people took part before the study was stopped early. The main goals were to check safety and wheth…

This early-phase study tested whether adding IL-12 gene therapy to the immunotherapy drug atezolizumab could help people with advanced non-small cell lung cancer whose disease had worsened after initial immunotherapy. The trial enrolled 13 adults and focused on safety and how lon…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors like ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-stage study tested a new drug called AUR106 in 21 adults with advanced solid tumors like lung, stomach, bladder, kidney, colon, or esophageal cancer that had come back. The main goals were to find a safe dose and check for side effects. The study was stopped early, so …

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to see if the treatment was safe and to look for early signs of tumor shrinkag…

This study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial was stopped early, so results are limited. It involved 102 adults who had not received prior chemotherap…

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or with other cancer drugs to see if it was safe and could shrink tumors. The study was terminated early, so results are limited.

This early-phase study tested an experimental drug (PF-07265028) alone or with another drug (sasanlimab) in 21 people with advanced solid tumors like lung, stomach, or bladder cancer. The goal was to find the safest dose and see if the drugs shrink tumors. The study was stopped e…

This study tested a new combination of two drugs (ociperlimab and tislelizumab) against a standard drug (pembrolizumab) for people with advanced non-small cell lung cancer that had not been treated before. The trial aimed to see if the combo could help patients live longer or slo…

This early-stage trial tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in people with advanced solid tumors that have specific KRAS gene mutations. The goal was to check safety and how the body processes the drug. The study was stopped early, so results…

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This early-stage study tested a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The drug works by breaking down the faulty EGFR protein that drives cancer growth. The trial aimed to find safe doses and check for early…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise radiation therapy (SBRT) could help people with early-stage non-small cell lung cancer who cannot have surgery. About 448 adults took part, but the trial was stopped early. The goal was to…

This study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers. It included 77 adults with Merkel cell, skin, lung, breast, or throat cancer. The study was termi…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced non-small cell lung cancer that had spread. The goal was to see if these drugs could control the cancer without needing chemotherapy. Only 5 people took part before the study was stopped …

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early-phase study tested a new drug, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study …

This early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This study tested whether giving a higher radiation dose directly to the lung tumor, while keeping standard doses to surrounding areas, is safe for people with non-small cell lung cancer. Six participants received this targeted dose escalation along with chemotherapy. The goal wa…

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This study tested a combination of two targeted drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their c…

This study tested whether monitoring daily step counts in people with stage III non-small cell lung cancer during chemoradiotherapy helps doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the study was s…

This study looked at whether a program combining different types of exercise could help people with advanced lung cancer feel less tired, move better, and have a better quality of life. It was designed for adults with stage III or metastatic non-small cell lung cancer who were al…

This study tested a mobile app called Apricity CARE to help ethnic and racial minority patients with non-small cell lung cancer report side effects from immunotherapy. The goal was to reduce treatment delays and hospital visits. The study was stopped early, but it aimed to improv…

This observational study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to gather information to help develop a digital tool that could spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur…

This study looked at how long to continue immunotherapy in people with advanced non-small cell lung cancer who had already responded well to treatment for 6 to 12 months. The goal was to see if stopping or continuing treatment made a difference in keeping the cancer from growing.…